Dr Reddy’s Laboratories has agreed to acquire a portfolio of 42 approved, non-marketed abbreviated new drug applications (ANDAs) in the US, which includes more than 30 generic injectable products, from an undisclosed seller.
The generic injectable products would need technology transferred and may be launched within 1-2 years.
According to IQVIA, the value of the total addressable market for the generic injectable products in the US is nearly $645 million for the year 2018.
Erez Israeli – Chief Operating Officer of Dr. Reddy’s Laboratories, said: “The acquisition is in line with our stated strategy to significantly enhance our portfolio in our chosen growth markets. This transaction will help augment our injectables product portfolio in the U.S. market and globally.”